Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2014 Feb 1;120(3):381-9.
doi: 10.1002/cncr.28352. Epub 2013 Dec 23.

Patient-reported outcomes in women with breast cancer enrolled in a dual-center, double-blind, randomized controlled trial assessing the effect of acupuncture in reducing aromatase inhibitor-induced musculoskeletal symptoms

Ting Bao  1 , Ling Cai, Claire Snyder, Kelly Betts, Karineh Tarpinian, Jeff Gould, Stacie Jeter, Michelle Medeiros, Saranya Chumsri, Aditya Bardia, Ming Tan, Harvinder Singh, Katherin H R Tkaczuk, Vered Stearns
Affiliations
Randomized Controlled Trial

Patient-reported outcomes in women with breast cancer enrolled in a dual-center, double-blind, randomized controlled trial assessing the effect of acupuncture in reducing aromatase inhibitor-induced musculoskeletal symptoms

Ting Bao et al. Cancer. .

Abstract

Background: Aromatase inhibitors (AIs) have been associated with decrements in patient-reported outcomes (PROs). The objective of this study was to assess whether real acupuncture (RA), compared with sham acupuncture (SA), improves PROs in patients with breast cancer who are receiving an adjuvant AI.

Methods: Postmenopausal women with a stage 0 through III breast cancer who received an AI and had treatment-associated musculoskeletal symptoms were randomized to receive 8 weekly RA versus SA in a dual-center, randomized controlled trial. The National Surgical Adjuvant Breast and Bowel Project (NSABP) menopausal symptoms questionnaire, the Center for Epidemiological Studies Depression (CESD) scale, the Hospital Anxiety and Depression Scale (HADS), the Pittsburgh Sleep Quality Index (PSQI), the hot flash daily diary, the Hot Flash-Related Daily Interference Scale (HFRDI), and the European quality-of-life survey (EuroQol) were used to assess PROs at baseline and at 4weeks, 8 weeks, and 12 weeks.

Results: The intention-to-treat analysis included 23 patients in the RA arm and 24 patients in the SA arm. There were no significant differences in baseline characteristics between the 2 groups. Compared with baseline, scores in the RA arm improved significantly at week 8 on the CESD (P = .022), hot flash severity (P = .006), hot flash frequency (P = .011), the HFRDI (P = .014), and NSABP menopausal symptoms (P = .022); scores in the SA arm improved significantly on the EuroQol (P = .022),the HFRDI (P = .043), and NSABP menopausal symptoms (P = .005). Post-hoc analysis indicated that African American patients (n = 9) benefited more from RA than SA compared with non-African American patients (n = 38) in reducing hot flash severity (P < .001) and frequency (P < .001) scores.

Conclusions: Both RA and SA were associated with improvement in PROs among patients with breast cancer who were receiving AIs, and no significant difference was detected between arms. Racial differences in response to acupuncture warrant further study.

Keywords: acupuncture; aromatase inhibitor; musculoskeletal symptoms; patient-reported outcomes.

PubMed Disclaimer

Conflict of interest statement

Disclosure of Conflicts of Interest:

Dr. Saranya Chumsri has consultant/advisory role in Novartis, and receives research funding from Novartis, GSK, Merck; Dr. Vered Stearns receives research funding from Pfizer, Novartis.

Figures

Fig 1
Fig 1
Consort Diagram
Fig 2
Fig 2
Forrest plots for the subgroup analysis Fig 2 showed forest plots for the subgroup analysis based on BMI, age and race displaying treatment effects across subgroups. Dotted vertical line shows no effect point, and bold vertical line shows overall treatment effect point. Number of patients (SA/RA) from up to down on the Y-axis is 5/4, 19/19, 21/20, 3/3, 11/14 and 7/8.
Fig 2
Fig 2
Forrest plots for the subgroup analysis Fig 2 showed forest plots for the subgroup analysis based on BMI, age and race displaying treatment effects across subgroups. Dotted vertical line shows no effect point, and bold vertical line shows overall treatment effect point. Number of patients (SA/RA) from up to down on the Y-axis is 5/4, 19/19, 21/20, 3/3, 11/14 and 7/8.
Fig 3
Fig 3
Interaction plot illustrating different racial response to real vs sham acupuncture in hot flash scores
Fig 3
Fig 3
Interaction plot illustrating different racial response to real vs sham acupuncture in hot flash scores
See this image and copyright information in PMC

References

    1. Burstein HJ, et al. American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2010;28(23):3784–96. - PMC - PubMed
    1. Morales L, et al. Acute effects of tamoxifen and third-generation aromatase inhibitors on menopausal symptoms of breast cancer patients. Anticancer Drugs. 2004;15(8):753–60. - PubMed
    1. Fallowfield L, et al. Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2004;22(21):4261–71. - PubMed
    1. Fallowfield LJ, et al. Quality of life in the intergroup exemestane study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2006;24(6):910–7. - PubMed
    1. Whelan TJ, et al. Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2005;23(28):6931–40. - PubMed

Publication types

Substances